Pulike Biological Engineering (603566) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.034x

Based on the latest financial reports, Pulike Biological Engineering (603566) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥87.38 Million ≈ $12.79 Million USD) by net assets (CN¥2.58 Billion ≈ $377.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Pulike Biological Engineering to measure how many days the company can operate on defensive assets alone.

Pulike Biological Engineering - Cash Flow Conversion Efficiency Trend (2010–2024)

This chart illustrates how Pulike Biological Engineering's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Pulike Biological Engineering Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pulike Biological Engineering ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Kunwu Jiuding Investment Holdings Co Ltd
SHG:600053
-0.037x
Yinchuan Xinhua Commercial Group Co Ltd
SHG:600785
0.170x
Kaufman Et Broad
PA:KOF
0.043x
Indonesian Paradise Property
JK:INPP
0.011x
GREENLIGHT CAP.RE A DL-01
F:G8L
0.050x
ST Barbara Ltd
AU:SBM
-0.031x
Andersen Group Inc.
NYSE:ANDG
-0.135x
Anhui Jinchun Nonwoven Co Ltd
SHE:300877
-0.067x

Annual Cash Flow Conversion Efficiency for Pulike Biological Engineering (2010–2024)

The table below shows the annual cash flow conversion efficiency of Pulike Biological Engineering from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Pulike Biological Engineering.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥2.63 Billion
≈ $384.28 Million
CN¥268.79 Million
≈ $39.33 Million
0.102x -1.41%
2023-12-31 CN¥2.72 Billion
≈ $398.59 Million
CN¥282.78 Million
≈ $41.38 Million
0.104x +27.22%
2022-12-31 CN¥2.80 Billion
≈ $409.51 Million
CN¥228.36 Million
≈ $33.42 Million
0.082x -30.87%
2021-12-31 CN¥1.80 Billion
≈ $263.46 Million
CN¥212.53 Million
≈ $31.10 Million
0.118x -22.92%
2020-12-31 CN¥1.71 Billion
≈ $250.17 Million
CN¥261.83 Million
≈ $38.31 Million
0.153x +81.24%
2019-12-31 CN¥1.66 Billion
≈ $242.62 Million
CN¥140.10 Million
≈ $20.50 Million
0.084x +9.45%
2018-12-31 CN¥1.64 Billion
≈ $239.34 Million
CN¥126.27 Million
≈ $18.48 Million
0.077x -14.02%
2017-12-31 CN¥1.57 Billion
≈ $229.57 Million
CN¥140.86 Million
≈ $20.61 Million
0.090x -47.45%
2016-12-31 CN¥1.48 Billion
≈ $216.71 Million
CN¥253.03 Million
≈ $37.03 Million
0.171x +22.12%
2015-12-31 CN¥1.34 Billion
≈ $195.68 Million
CN¥187.09 Million
≈ $27.38 Million
0.140x -36.75%
2014-12-31 CN¥683.59 Million
≈ $100.03 Million
CN¥151.21 Million
≈ $22.13 Million
0.221x -26.36%
2013-12-31 CN¥603.33 Million
≈ $88.29 Million
CN¥181.21 Million
≈ $26.52 Million
0.300x -10.59%
2012-12-31 CN¥440.47 Million
≈ $64.45 Million
CN¥147.96 Million
≈ $21.65 Million
0.336x -31.46%
2011-12-31 CN¥311.26 Million
≈ $45.55 Million
CN¥152.54 Million
≈ $22.32 Million
0.490x +35.24%
2010-12-31 CN¥195.88 Million
≈ $28.66 Million
CN¥70.98 Million
≈ $10.39 Million
0.362x --

About Pulike Biological Engineering

SHG:603566 China Biotechnology
Market Cap
$500.83 Million
CN¥3.42 Billion CNY
Market Cap Rank
#12365 Global
#3632 in China
Share Price
CN¥9.89
Change (1 day)
+1.12%
52-Week Range
CN¥9.78 - CN¥15.51
All Time High
CN¥34.10
About

Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China.